On 30 January 2014 the Court of Justice of the European Union (“CJEU”) handed down two Decisions in response to two preliminary rulings sought by the same Greek Court that referred the questions answered by the CJEU in its Judgment of 18 July 2013 (Case C‑414/11, Daiichi Sankyo Co. Ltd, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon). In this case, the Greek Court, which was hearing a matter involving a patent that had been granted on 21 October 1986, sought the guidance of the CJEU on whether under Articles 27 and 70 of the TRIPs Agreement a patent protecting a process to obtain a pharmaceutical product would protect the product as such after t [...]
On 22 October 2013 the Provincial Court of Barcelona (Section 15) handed down a controversial judgment revoking a patent due to lack of inventive activity relying on a technical report prepared by an expert acknowledged not to be an expert in the technical field of the invention. According to the judgment “[...] for an expert to be able to provide the point of view of the person skilled in the art – necessary in this case to assess the inventive activity -, it is not essential for the expert to be an expert but that, due to his training and experience, he is capable of putting himself in the position of the «person skilled in the art».”
This point of view is at odds with the conclusio [...]
UPC aficionados will be interested to learn that the 16th draft of the Rules of Procedure was unveiled yesterday.
Readers will remember that the previous draft was published on 31 May 2013. Since then, the Drafting Committee has been working on a new draft that may – or may not – accommodate the comments received from stakeholders, including those discussed at the European Judge’s Forum that took place in Venice on 25-26 October 2013. Trying to comment on the 382 Rules of the draft in this very brief blog would be like trying to sum-up the history of mankind in a haiku. So this author will focus his attention on one aspect that appears to be here to stay: the obstinate “opting-out” fee. [...]
The readers will recall that on 18 July 2013, the European Court of Justice (“ECJ”) handed down its controversial judgment in case C‑414/11 Daiichi Sankyo Co. Ltd, Sanofi-Aventis Deutschland GmbH v. DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon. In this judgment the ECJ, making a 180º twist in relation to the criteria endorsed in Opinion 1/1994, in its judgment of 14 December 2000 and in its judgment of 11 September 2007, concluded that TRIPS’ provisions on patents now fall within the realm of the European Union (“EU”) common commercial policy. This is a rather surprising conclusion to reach, taking into account that in paragraph 46 of its judgment of 11 September 2007 the ECJ [...]
The Court of Appeal of Burgos dismissed the appeal against the Judgment of the Provincial Court of Burgos, which upheld a patent for a pharmaceutical composition and its use, despite the fact that clinical trials regarding the patented composition and the patented use were mentioned in the prior art.
One of the “co-lateral” damages expected from the latest Pixar Films’ type of productions coming from the European Commission (the European patent with unitary effect and the Unified Patent Court (“UPC”) fostered by the Commission behind the scenes) is the increase of patent applications filed before national patent offices. Stakeholders are growing concerned that the final product looks more like “Monsters Inc.” (it may be an irony of destiny that the first known patent was granted to a boat called “The Monster”!) than like the expected promised land.
Against this background, the recent publication of a new draft of the “Patent Act” by the Spanish Patent and Trademark Office (“SPTO”) may [...]